Phase 4
Completed N=70
Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity
Obesity
Source: ClinicalTrials.gov NCT04614545 ↗
Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Dec 2022
Primary outcomePrimary: Change in Body Weight (Percentage) — -6.61; -7.68 mean change in body weight (%)
◆ Published Evidence
Highly cited
1,808citations · ~121 / year
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.
Summary
This study will study the effects associated with the prescription of phentermine in a virtual setting, comparing with prescription of phentermine via a standard face-to-face visit for patients with obesity or overweight.
Linked Publications (5)
-
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.
-
Pharmacological management of obesity: an endocrine Society clinical practice guideline.
-
The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity.
-
THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.
-
The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Body Weight (Percentage) |
-6.61; -7.68 | — |
| SECONDARY Adherence to Weight Management Program |
82.9; 62.9 | — |
| SECONDARY Adherence to Medication Use |
93.3; 83.3 | — |
| SECONDARY Percentage of Patients That Tolerated Full Dosage of Phentermine (37.5mg) |
85.7; 90 | — |
| SECONDARY Percentage of Patients Who Achieved More Than 5% Weight Loss Over the Course of the Study (12 Weeks) |
64.7; 70.5 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18-65 years old
- Body mass index (BMI) greater than or equal to 27 with 1 or more comorbidities (hypertension, diabetes, sleep apnea, fatty liver disease, PCOS, dyslipidemia, congestive heart failure, osteoarthritis) OR a BMI or 30 or greater
- Able to log into an online platform or have a smartphone
- Willing to join a virtual weight management program
Exclusion Criteria
- Contraindication for use of phentermine
- Female who is pregnant, breast-feeding, or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods
- Participation in another clinical trial within 30 days of screening
- Cardiovascular disease including uncontrolled hypertension or history of arrhythmias
- Treatment with any medication with the intention of weight loss within 180 days before screening
- Use of Topiramate within 180 days of screening
- Previous history of bariatric surgery or use of minimally invasive weight loss devices
Data sourced from ClinicalTrials.gov (NCT04614545) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.